412 related articles for article (PubMed ID: 10494894)
1. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.
Izzo AA; Mascolo N; Capasso R; Germanò MP; De Pasquale R; Capasso F
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):221-3. PubMed ID: 10494894
[TBL] [Abstract][Full Text] [Related]
2. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats.
Germanò MP; D'Angelo V; Mondello MR; Pergolizzi S; Capasso F; Capasso R; Izzo AA; Mascolo N; De Pasquale R
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):241-4. PubMed ID: 11218077
[TBL] [Abstract][Full Text] [Related]
4. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors.
Abalo R; Cabezos PA; Vera G; López-Miranda V; Herradón E; Martín-Fontelles MI
Neurogastroenterol Motil; 2011 May; 23(5):457-67, e177. PubMed ID: 21303434
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat.
Coruzzi G; Adami M; Coppelli G; Frati P; Soldani G
Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):715-8. PubMed ID: 10619190
[TBL] [Abstract][Full Text] [Related]
7. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.
Landi M; Croci T; Rinaldi-Carmona M; Maffrand JP; Le Fur G; Manara L
Eur J Pharmacol; 2002 Aug; 450(1):77-83. PubMed ID: 12176112
[TBL] [Abstract][Full Text] [Related]
8. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
9. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development.
Yang ZM; Paria BC; Dey SK
Biol Reprod; 1996 Oct; 55(4):756-61. PubMed ID: 8879486
[TBL] [Abstract][Full Text] [Related]
10. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis.
Gross A; Terraza A; Marchant J; Bouaboula M; Ouahrani-Bettache S; Liautard JP; Casellas P; Dornand J
J Leukoc Biol; 2000 Mar; 67(3):335-44. PubMed ID: 10733093
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments.
Yousif MH; Oriowo MA
Pharmacol Res; 1999 Nov; 40(5):415-21. PubMed ID: 10527656
[TBL] [Abstract][Full Text] [Related]
12. Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors.
Izzo AA; Mascolo N; Borrelli F; Capasso F
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):65-70. PubMed ID: 9933153
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids.
Szabo B; Siemes S; Wallmichrath I
Eur J Neurosci; 2002 Jun; 15(12):2057-61. PubMed ID: 12099913
[TBL] [Abstract][Full Text] [Related]
14. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Fattore L; Cossu G; Martellotta CM; Fratta W
Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
[TBL] [Abstract][Full Text] [Related]
15. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Héaulme M; Shire D; Calandra B; Congy C; Martinez S; Maruani J; Néliat G; Caput D
FEBS Lett; 1994 Aug; 350(2-3):240-4. PubMed ID: 8070571
[TBL] [Abstract][Full Text] [Related]
16. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Burgos E; Pascual D; Martín MI; Goicoechea C
Eur J Pain; 2010 Jan; 14(1):40-8. PubMed ID: 19318283
[TBL] [Abstract][Full Text] [Related]
17. Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat.
Abalo R; Cabezos PA; López-Miranda V; Vera G; González C; Castillo M; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2009 Sep; 21(9):1002-e80. PubMed ID: 19413685
[TBL] [Abstract][Full Text] [Related]
18. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
Pozzi O; Misiano P; Clark GD; Visentin L
Pharmacology; 2003 Nov; 69(3):158-63. PubMed ID: 14512703
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms.
Johanek LM; Heitmiller DR; Turner M; Nader N; Hodges J; Simone DA
Pain; 2001 Sep; 93(3):303-315. PubMed ID: 11514089
[TBL] [Abstract][Full Text] [Related]
20. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
Rawls SM; Cabassa J; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
